Most reported studies uNlising the MAM workflow have been performed using monoclonal anNbodies (mAbs) as the analyNcal target molecule . The MAM workflow is capable of being adapted and used for different biotherapeuNc molecules, such as fusion proteins. Currently, there are limited reports available that specifically focus on MAM for fusion proteins . For this work, a Glucagon-like pepNde (GLP)-Fc fusion protein drug was used as the target analyte to develop a MAM workflow for the idenNficaNon and quanNtaNon of CQAs.